5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Lyka Labs Ltd.

•
lykalabs.comBSE: 500259NSE: LYKALABS
Market Cap₹ 298 Cr.
Current Price
High / Low₹ 102 / 44
Stock P/E0.0
Book Value₹ 25
Price to Book1.85
Dividend Yield0.00 %
ROCE-20.3 %
ROE-31.1 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2023 • Formulations: 96.3% • Bulk Drugs: 3.7%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Working capital cycle has improved - days down from 68 to 21

CONS

  • Company is loss-making at the operating / net level
  • Recent results are weak - TTM profit is down 735.8% versus prior year
  • Company has a low return on equity of -8.9% over last 3 years
  • Company has a low return on capital employed of -3.1%
  • Interest coverage is weak at -9.0x - earnings barely cover interest
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.25x)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.LYKALABS82.510.00298.300.002.05105.5242.3128.09-5.9610.75
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
21273127304133312933312842
19232625263628272636293341
Operating Profit346245533-32-42
OPM %12.05%14.72%18.65%8.19%13.48%12.97%15.43%10.81%11.62%-9.58%6.22%-15.98%3.72%
00101011111-220
Interest1111111111111
Depreciation3333222122222
Profit before Tax-2-02-123421-50-302
Tax %-2.38%34.09%43.33%-33.88%25.53%24.46%24.79%43.58%30.77%24.38%0.00%0.43%-5.37%
Net Profit-2-01-222311-40-302
-0.54-0.100.40-0.500.490.690.750.340.22-1.020.08-8.340.58

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
784241416216481106135121134
5642404448676592117123138
Operating Profit22-11-31497161517-2-4
OPM %27.90%-1.24%2.21%-7.89%23.17%59.32%19.36%13.69%12.93%-1.99%-3.10%
-032-251-2-423-19-20
Interest1786192620125233
Depreciation66488151412788
Profit before Tax-1-11-7-55-1860-13-111-33-32
Tax %66.54%3.41%124.41%-0.43%21.40%33.76%-0.59%-143.32%28.68%2.85%4.34%
Net Profit-0-112-55-1440-13-28-32-31
EPS0.000.000.000.00-5.0813.87-4.65-0.692.22-9.05—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
8%
5 Years:
14%
3 Years:
14%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
2%
5 Years:
2%
3 Years:
-9%
1 Year:
-17%

RETURN ON EQUITY

10 Years:
-12%
5 Years:
22%
3 Years:
-9%
Last Year:
-31%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

No bonus data found

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22282829292931333636
526870-10-241628578551
7543931561718576573643
Trade Payables282122171298111417
65832618107036282224
Total Liabilities242243238209197209179186193171
868176102959066568587
Capital Work in Progress171718171616152202
6262623232323232150
9766487101214
0000000264033
Cash & Bank10087159611
66757644424650353834
Total Assets242243238209197209179186193171

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
21719-1267773-25
Cash from Investing-5-3-300-47-9-11-9
Cash from Financing-15-4-1620-8-63-20384
-0-1-08-29-7-3-5-0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
58.1058.1058.1058.1658.1658.1658.1658.1658.45
0.150.150.150.240.160.170.170.290.17
0.750.660.660.660.660.660.660.660.66
Government0.000.000.000.000.000.000.000.000.00
40.9941.0841.0740.9441.0141.0041.0040.8840.72

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-11
Shareholders meeting

2026-08-11 - Lyka Labs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 10, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-11
General Updates

2026-08-11 - Lyka Labs Limited has informed the Exchange about General Updates

2026-08-10
Shareholders meeting

2026-08-10 - Lyka Labs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026

2026-08-10
General Updates

2026-08-10 - Lyka Labs Limited has informed the Exchange about General Updates

2026-08-10
Outcome of Board Meeting

2026-08-10 - Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-07-20
Copy of Newspaper Publication

2026-07-20 - Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-17
General Updates

2026-07-17 - Lyka Labs Limited has informed the Exchange about General Updates

2026-07-17
General Updates

2026-07-17 - Lyka Labs Limited has informed the Exchange about General Updates

News

Recent coverage and analyst commentary for LYKALABS

Loading news…

🤖

AI Stock Analyst

Lyka Labs Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login